Abstract:The equine infectious anemia virus (EIAV) attenuated vaccine was developed by long-term passaging of a field-isolated virulent strain in cross-species hosts, followed by successive cultivation in cells in vitro To explore the molecular mechanism underlying the evolution of the EIAV attenuated vaccine, a systematic study focusing on long-terminal-repeat (LTR) variation in numerous virus strains ranging from virulent EIAV to attenuated EIAV was performed over time both in vitro and in vivo Two hypervariable regions were identified within the U3 region in the enhancer region (EHR) and the negative regulatory element (NRE) and within the R region in the transcription start site (TSS) and the Tat-activating region (TAR). Among these sites, variation in the U3 region resulted in the formation of additional transcription factor binding sites; this variation of the in vitro-adapted strains was consistent with the loss of pathogenicity. Notably, the same LTR variation pattern was observed both in vitro and in vivo Generally, the LTR variation in both the attenuated virus and the virulent strain fluctuated over time in vivo Interestingly, the attenuated-virus-specific LTR variation was also detected in horses infected with the virulent strain, supporting the hypothesis that the evolution of an attenuated virus might have involved branching from EIAV quasispecies. This hypothesis was verified by phylogenetic analysis. The present systematic study examining the molecular evolution of attenuated EIAV from EIAV quasispecies may provide an informative model reflecting the evolution of similar lentiviruses.IMPORTANCE The attenuated EIAV vaccine was the first lentiviral vaccine used to successfully control for equine infectious anemia in China. This vaccine provides an important reference for studying the relationship between EIAV gene variation and changes in biological characteristics. Importantly, the vaccine provides a model for the investigation of lentiviral quasispecies evolution. This study followed the "natural" development of the attenuated EIAV vaccine by use of a systematic analysis of LTR evolution in vitro and in vivo The results revealed that the increase in LTR variation with passaging was accompanied by a decrease in virulence, which indicated that LTR variability might parallel the attenuation of virulence. Interestingly, the attenuated-virus-specific LTR variation was also detected in virulent-strain-infected horses, a finding consistent with those of previous investigations of gp90 and S2 evolution. Therefore, we present a hypothesis that the evolution of the attenuated virus may involve branching from EIAV quasispecies present in vivo.

A Pilot Study Comparing the Development of EIAV Env-Specific Antibodies Induced by DNA/Recombinant Vaccinia-Vectored Vaccines and an Attenuated Chinese EIAV Vaccine

A Pilot Study on an Attenuated Chinese EIAV Vaccine Inducing Broadly Neutralizing Antibodies

An Attenuated EIAV Vaccine Strain Induces Significantly Different Immune Responses from Its Pathogenic Parental Strain Although with Similar in Vivo Replication Pattern

Combined immunity of DNA vector and recombinant vaccinia virus expressing Gag proteins of equine infectious anemia virus

A Proviral Derivative from a Reference Attenuated EIAV Vaccine Strain Failed to Elicit Protective Immunity

Combination Immunization with EIAV Env Protein Expressed by Recombinant Baculovirus and Recombinant Vaccinia Virus Containing Env Gene

Transient Immune Suppression of Inapparent Carrier Ponies Inoculated with Attenuated Equine Infectious Anemia Virus Infectious Clone.

Study on the Infectivity of Vaccinia Virus in Equine Cells

[Induction of EIAV-specific Cellular Immune Response by Attenuated EIAV Vaccine].

Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV

[Elevation of IFN-gamma Transcription Level in Peripheral Blood Mononuclear Cells of EIAV Vaccinated Horses].

Long Terminal Repeat Sequences from Virulent and Attenuated Equine Infectious Anemia Virus Demonstrate Distinct Promoter Activities.

In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine

Enhanced Immune Responses to E2 Protein and DNA Formulated with ISA 61 VG Administered As a DNA Prime–protein Boost Regimen Against Bovine Viral Diarrhea Virus

Efficacy of Dna Vaccination Against Western Equine Encephalitis Virus Infection

Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies in Vitro and in Vivo.

Cloning and sequencing of the full genome of equine infectious anemia virus provirus DNA

A Pilot Study on Interaction Between Donkey Tetherin and EIAV Stains with Different Virulent and Replication Characteristics.

[Expression and Immunogenicity of Equine Infectious Anemia Virus Membrane Protein GP90].

Amino Acid Mutations of the Infectious Clone from Chinese EIAV Attenuated Vaccine Resulted in Reversion of Virulence.

Elevation of IL-2 Expressing Level in PBMC of EIAV Vaccinated Horses